checkAd

     193  0 Kommentare Cardiff Oncology to Present at Upcoming Investor Conferences in May

    SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024.

    Details of the presentations can be found below.

    H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    Location: The Nasdaq Headquarters, New York City
    Presenter: Mark Erlander, CEO
    Format: Fireside Chat
    Date: 05/20/2024
    Time: 2:30 PM ET

    Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
    Location: Virtual
    Presenter: Mark Erlander, CEO
    Format: Fireside Chat
    Date: 05/29/2024
    Time: 1:30 PM ET

    Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replays will be available after the conclusion of the respective presentations.

    About Cardiff Oncology, Inc.

    Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

    Lesen Sie auch

    Cardiff Oncology Contact:
    James Levine
    Chief Financial Officer
    858-952-7670
    jlevine@cardiffoncology.com

    Investor Contact:
    Kiki Patel, PharmD
    Gilmartin Group
    332-895-3225
    Kiki@gilmartinir.com

    Media Contact:
    Grace Spencer
    Taft Communications
    609-583-1151
    grace@taftcommunications.com




    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Cardiff Oncology to Present at Upcoming Investor Conferences in May SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) - Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will …